Risk runs high, but so does the upside. Biotech investing thrives on bold bets and breakthrough data. On October 30, 2025, a wave of clinical-stage and commercial biopharma stocks surged to new 52-week highs, driven by breakthrough trial data, strategic deals, and earnings surprises. From obesity and CNS therapies to rare disease advances and acquisition drama, these moves reflect more than momentum; they signal conviction. Do you have these names on your watchlist? And more importantly, will they keep cli ...